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Abstract
The development of accurate clinical biomarkers has been challenging in part due to the diversity between patients and
diseases. One approach to account for the diversity is to use multiple markers to classify patients, based on the concept that
each individual marker contributes information from its respective subclass of patients. Here we present a new strategy for
developing biomarker panels that accounts for completely distinct patient subclasses. Marker State Space (MSS) defines
‘‘marker states’’ based on all possible patterns of high and low values among a panel of markers. Each marker state is
defined as either a case state or a control state, and a sample is classified as case or control based on the state it occupies.
MSS was used to define multi-marker panels that were robust in cross validation and training-set/test-set analyses and that
yielded similar classification accuracy to several other classification algorithms. A three-marker panel for discriminating
pancreatic cancer patients from control subjects revealed subclasses of patients based on distinct marker states. MSS
provides a straightforward approach for modeling highly divergent subclasses of patients, which may be adaptable for
diverse applications.
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Introduction
The development of accurate biomarkers is increasingly
important with the growth of molecular and personalized
medicine [1]. Biomarkers are needed for diverse areas such as
risk assessment, early detection, differential diagnosis, disease
staging and prognostication, treatment selection, and treatment
monitoring [1,2]. The development of cancer drugs that are
targeted to specific molecules is now generally accompanied by the
development of companion diagnostic biomarkers that can select
the patients most likely to benefit from the drug or can monitor the
efficacy of the drug [3,4]. A biomarker can consist of any
measurable physical quantity, such as cell counts or nodal status,
but modern efforts at biomarker development are mainly focused
on specific molecules within the classes of DNA, RNA, proteins,
carbohydrates, lipids, and metabolites. Molecular entities may
provide more objectivity and accuracy than traditional modes of
evaluation, since specific molecules may be functionally involved
in the mechanism of the pathology.
A challenge in the development of molecular biomarkers arises
from the diversity between people in the molecules that are present
in disease. Because of variation between people in genetics,
environment, and disease status, any single molecular biomarker
usually does not provide an accurate diagnosis for every individual.
An example is prostate specific antigen, which is routinely used to
screen for prostate cancer, but is frequently elevated in non-
cancerous conditions and not elevated in some cancers [5]. A
common approach for addressing this challenge is to use multiple
molecular biomarkers together in a single biomarker panel [6].
The rationale for that approach is that the diversity between
people can be accounted for through multiple biomarkers, each of
which contributes information for a particular subset of the
population. The potential for improved accuracy of combination
biomarkers over single biomarkers has been demonstrated in
numerous cases.
A critical consideration in the development of combination
biomarkers is how individual markers should be selected and what
rules should be used in bringing them together. The concept of
using multiple factors to model and predict classes has been
extensively studied in many different fields, and many systems
have been developed. In the field of biomarker discovery,
frequently used techniques are recursive partitioning, linear
discriminant analysis, and logistic regression [6,7]. All have been
used to search for combinations of biomarkers for various types of
cancer, including lung [8,9,10], prostate [8,11], breast [8],
colorectal [8], and gastric [8] cancers. Recursive partitioning
provides a straightforward classification method and can function
despite missing data values. Additionally, though the selection of
markers can be unstable with certain data sets [12], techniques
exist for optimizing this procedure [13,14]. Linear discriminant
analysis is robust but is limited by its assumption of a normal data
distribution and equal class covariance [15], which are difficult
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requirements to meet in a clinical setting. Logistic regression is
able to capture the scalar nature of many factors [16] but may not
accurately model sharp distinctions between patient subclasses.
Each has its own strengths and limitations when applied to the
development of a biomarker panel [16].
Here we present an alternative method for developing
biomarker panels, called Marker State Space (MSS). MSS is
designed with the recognition that subclasses of patients can have
completely distinct molecular characteristics, as observed with
several cancers [17,18,19]. To account for divergent subgroups,
MSS allows distinct ‘‘states’’ to exist within either the cases
(patients with disease) or the controls (unaffected subjects). A state
refers to the pattern of high and low values among a set of
markers, and the state space is the set of all possible patterns. By
defining certain states as case states and others as control states, all
subclasses of molecular diversity are encompassed within a set of
markers. This method is distinguished from other methods of
classifier development by its systematic categorization of all
possible patterns of biomarker levels using binary (high or low)
values.
The purpose of the present study was to determine if the MSS
approach could identify robust multi-marker panels and molecular
subclasses of patients. We developed software for identifying
biomarker panels using MSS and tested the method in the
development of a biomarker panel for differentiating patients with
pancreatic cancer from those with a benign condition of the
pancreas such as pancreatitis. Such biomarkers are needed
because of the clinical similarity between those conditions and
the critical need to make accurate diagnoses as early as possible
[20]. The marker data were acquired using a method for detecting
glycan levels on the proteins captured by the antibody microarrays
[21,22,23], which has the potential for enhanced biomarker
performance relative to conventional protein detection [22,24].
We demonstrate that biomarker panels developed using MSS are
robust in cross validation and training-set/test-set analyses and
that MSS provides a novel approach for identifying patient
subclasses based on marker states.
Experimental Section
Biological reagents
The antibodies and proteins were purchased from various
sources (Table S1). The antibodies were purified by dialysis (Slide-
A-Lyzer, Pierce Biotechnology, Rockford, IL) against PBS buffer
followed by ultracentrifugation. The concentration of each
antibody was adjusted to 250 mg/ml prior to printing. The
integrity and purity of each antibody was confirmed by SDS-
PAGE under reducing and non-reducing conditions. The manu-
facturers characterized the specificities and optimal applications of
most of the antibodies, and we performed Western blot and
dilution series analyses for a subset of them [25,26]. Antibody
biotinylation was performed using EZ-Link sulfo-NHS-LC-biotin
(sulfosuccinimidyl-6-(biotinamido) hexanoate (Pierce Biotechnolo-
gy, Rockford, IL).
Plasma samples
Plasma samples (using EDTA as the anti-coagulant) from the
University of Pittsburgh School of Medicine were collected from
pancreatic cancer, pancreatitis and healthy subjects. Early-stage
cancer was defined as stages I and II, and late-stage cancer was
defined as stages III and IV. The pancreatitis patients were a
mixture of chronic and acute. The control subjects were healthy
with no evidence of pancreatic, biliary or liver disease. The
samples at each site were collected using a standard operating
procedure based on the serum and plasma protocols from the
Early Detection Research Network. All samples were stored at
280uC and sent frozen on dry ice. Each aliquot had been thawed
no more than three times before use.
Ethics statement
All sample collection and research was conducted under
protocols approved by the Institutional Review Boards at
Evanston Northwestern Healthcare, the University of Pittsburgh
School of Medicine, and the Van Andel Research Institute.
Written, informed consent was obtained from all participants in
the study.
Antibody-array assays
Antibody microarrays were prepared to detect glycan levels on
captured proteins and glycans. A piezoelectric non-contact printer
(2470 Arrayer, Aushon Biosystems, Billerica, MA) was used to spot
,350 pl of each antibody solution on the surfaces of ultrathin
nitrocellulose-coated glass microscope slides (PATH slides, GenTel
Biosciences, Madison, WI). Forty-eight identical arrays were
printed on each slide with each array consisting of 16–48 different
antibodies as well as control immunoglobulins from several species
printed in triplicate. A wax border was imprinted around each of
the arrays to define hydrophobic boundaries (SlideImprinter, The
Gel Co., San Francisco, CA). The printed slides were stored at 4
uC in a desiccated, vacuum-sealed slide box until use.
Antibody-array assays were performed to measure glycan levels
on either captured proteins or captured glycans (Fig. S1). Serum
samples were diluted with PBS buffer containing 0.1% Brij, 0.1%
Tween 20, and 50 mg/mL protease inhibitor mixture (Roche
Applied Science, Indianapolis, IN). A blocking solution consisting
of final concentrations of 400 mg/mL goat, mouse, and sheep IgG;
400 mg/mL chicken IgY; and 800 mg/mL rabbit IgG was included
in each serum or plasma sample to reduce nonspecific binding to
the printed antibodies. Slides were blocked with 7mL PBS with
0.5% Tween 20 (PBST0.5) and 1% BSA for 1 hr at room
temperature with gentle shaking. The slides were washed in three
changes of PBST0.5 for 3 min each with rocking. Six microliters of
each sample solution were incubated on each array overnight at
4uC. The slides were washed in three changes of PBST0.1 for 3
min each with rocking. Captured antigens were detected with
biotinylated antibodies at a concentration of 3 mg/mL followed by
incubation with 2 mg/mL streptavidin-phycoerythrin (Roche
Applied Science, Indianapolis, IN) using incubation and wash
conditions as above. The slides were scanned for fluorescence
emission at 532 nm using a microarray scanner (LS Reloaded,
Tecan, Ma¨nnedorf, Switzerland). All arrays were scanned
concurrently at a single laser power and detector PMT gain
setting.
Image data were quantified using GenePix Pro 5.1 (Molecular
Devices, Sunnyvale, CA). The net fluorescence signal was
calculated by subtracting the median local background surround-
ing each spot from the median intensity of the corresponding spot.
The signal intensities from replicate antibody measurements
within the same array were averaged (geometric mean). Antibodies
were removed from subsequent analysis that gave low signals over
most of the samples, defined as ,10% of samples giving signal at
least two-fold higher than the signal in the negative control array
(incubated with PBS instead of plasma).
Marker State Space program
The exhaustive marker search and selection algorithm has been
implemented in C/C++ using standard libraries and tested on
Linux and Mac OS platforms. The program exhaustively analyzes
Marker State Space
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all combinations of three markers, and all possible combinations of
thresholds for each marker within each group of three, to
determine a sensitivity and specificity for each combination. The
user specifies the step size for scanning through the thresholds and
the minimum specificity and sensitivity that is required for a
marker combination to be included in an output file. The program
also performs 10-fold cross validation and returns results from
each of the 10 splits of the analysis. Details of this procedure are
provided below. The software is available on request to the
authors.
Details of the marker selection program and procedures
The program first carries out a training process on all of the
sample data (‘‘full train’’) for all possible combinations of three
markers. For each marker, the program tests all possible thresholds
within that marker’s range of data values. The level of detail with
which this process is carried out can be customized using the
‘‘threshold step.’’ This variable sets the interval between successive
thresholds in the scanning process. For example, if a step is set at
0.5, a marker with log fluorescence values ranging from 1.25 to
3.25 will be tested with the thresholds of 1, 1.5, 2, 2.5, 3, and 3.5.
The threshold step can be increased to optimize the speed of the
program (as might be desired with a very large set of data) or it can
be decreased to achieve a greater level of detail in the results.
Once finished with the full train the program moves on to a 10-
fold cross validation testing process. The samples are randomly
divided into ten groups, or ‘‘splits,’’ of equal (or as close to equal as
possible) number. Data for nine of the ten groups are compiled
and used for training, examining all possible combinations of three
markers at all thresholds (using the same thresholds for each
marker that were used in the full train). The panels meeting or
exceeding a user-defined minimum performance are subsequently
tested against the remaining tenth split, where their accuracies are
recorded. This is repeated ten times, with each split serving as the
test set exactly one time.
Upon completion the program generates several text files; a
series of files for each split and for the full train. Almost all of the
information contained in these is compiled into two summary files.
A ‘‘final report’’ lists every panel generated (that met sensitivity/
specificity cut-offs), along with its sensitivity/specificity in the full
train, accuracy in each split (for any splits in which a panel did not
meet minimum performance N/A is reported in place of
accuracy), and average accuracy across the splits. A ‘‘detailed’’
file contains the classification rules, with a breakdown of the
samples populating each, for every panel that met the sensitivity/
specificity cut-offs. The remaining output files contain more details
regarding the ten splits, such as the samples used in each.
The strategy we developed for selecting the most robust marker
panel begins by sorting through the ‘‘final report,’’ opened as a
Microsoft Excel spreadsheet. The list of panels is trimmed to
include all the panels that tie for first or second best performance
in any of the ten splits. Using this trimmed list, the number of
appearances of each unique combination of three markers is
counted. This count represents the number of different thresholds
at which each set of three markers appeared as a top panel. The
ability of a panel to achieve high accuracy at several unique sets of
thresholds is an indicator of robustness, or insensitivity to slight
variations in sample data. A high average accuracy in the ten splits
is also an indicator of robustness, and so an average of each panel’s
average in the splits is calculated. Count and average accuracy in
the splits are compiled for each combination of three markers, and
the marker panel that performs best between the two categories is
selected for further validation.
Results
The Marker State Space method
The Marker State Space (MSS) method operates on a binary
system in which each individual marker is either high (1) or low (0),
based on a threshold for that marker (Fig. 1A). The state space is
the combinations of 1s and 0s that are possible for a certain
number of markers. A panel of two markers has four possible
states: 0,0; 0,1; 1,0; and 1,1; and a panel of three markers has eight
possible states: 0,0,0; 0,0,1; 0,1,0; 0,1,1; 1,0,0; 1,0,1; 1,1,0; and
1,1,1 (Fig. 1B). (Panels with more markers would have 2n possible
states, n being the number of markers.) A given sample occupies
exactly one state, depending on its pattern of high and low values
for each marker. In order to classify samples, each state is
designated as either a ‘‘case’’ state or a ‘‘control’’ state. For
example, in a two-marker panel, the state 0,0 could indicate
control samples, and the states 0,1; 1,0; and 1,1 could indicate case
samples (Figs. 1C and 1D).
The discovery of biomarker panels based on this classification
system requires a method for selecting the members of the marker
panel, the thresholds for each marker, and the state rules (the
designation of which states are cases and which states are controls).
These three factors, the markers, the thresholds, and the state
rules, are related to each other, so that changes in one might affect
the optimal values for the other two. An approach to selecting the
thresholds and state rules that best discriminate two groups of
samples is illustrated in Figure 2 for two markers. For each
individual marker, several test thresholds are applied to convert
the data to 1s and 0s (Fig. 2A). To determine which thresholds
work best together between the markers, all nine possible
combinations could be examined (Fig. 2B). For each of these
combinations, we can assign certain states to indicate cases and
other states to indicate controls. A simple approach to making
those assignments is to count how many case and control samples
populate each state, and then make the assignment accordingly
(Fig. 2B). For example, if state 0,1 is populated by six control
samples and only two case samples, the state would be assigned to
indicate controls. Once the assignment is made for each state, all
samples in each state are classified according to the assignments. A
sensitivity and specificity can be calculated based on how many
case and control samples were correctly classified.
The specificities and sensitivities of each of the combinations of
thresholds can be compared to determine which combination gave
the best discrimination between cases and controls (Fig. 2B). In the
example of Fig. 2, the use of threshold 2 for Marker 1 and
threshold 2 for Marker 2 gave perfect classification of the cases and
controls, but all of the other combinations of thresholds gave some
misclassifications.
The next level of selection occurs when data from multiple
candidate biomarkers are available. For example, when collecting
data from antibody microarrays, measurements from dozens of
antibodies might be acquired. To find the combination of markers
that work well together, a combinatorial search is required to test
the performance of various groupings of markers. For example, a
search for a two-marker panel among a dataset containing many
different markers could function by first testing Marker 1 with
Marker 2, covering all combinations of thresholds, then testing all
combinations of thresholds using Marker 1 with Marker 3, next
Marker 1 with Marker 4, etc. For a three-marker panel, many
more combinations are possible.
Because of the significant computation required to explore the
combinations of markers and thresholds that give the best
biomarker performance, we developed software to perform that
search. The initial version of the program was designed to search
Marker State Space
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for panels of three markers. This choice was made to keep down
the computation time and to gain more information about the
performance of the method with relatively simple panels. The user
may select the step size for scanning through the thresholds for
each marker, using linear steps through thresholds over log-
transformed data. The user also may select the minimal levels of
performance for a marker panel to be included in an output file.
Additional details of the operation and output of the software are
provided in the methods section.
MSS applied to the selection of a biomarker panel
The MSS method was applied to the discovery of a plasma
biomarker panel that could accurately distinguish cancer patients
from pancreatitis patients. Antibody microarray measurements
were acquired from 197 plasma samples, comprising 121 from
pancreatic cancer patients and 76 from pancreatitis patients. We
used a technique in which glycan levels are probed on the proteins
captured by antibody microarrays [21,22,23], owing to the
potential for enhanced biomarker performance relative to
conventional protein detection [22,24]. Each plasma sample was
incubated on an array containing 36 different capture antibodies
and control antibodies (Table S1), and the captured proteins were
probed with an anti-glycan antibody (Fig. S1). The capture
antibodies were chosen to target glycoproteins and glycan epitopes
that potentially have altered abundance in pancreatic cancer,
based on literature sources and our own previous research
[22,27,28,29,30,31]. Eight different anti-glycan detection antibod-
ies were used on each sample in individual arrays. The detection
antibodies targeted the CA 19-9 antigen (a polysaccharide called
sialyl-Lewis A) and related glycans such as Lewis blood group
structures and glycans from the ABO blood group system. These
glycans were chosen to determine whether other specific glycans in
additional to the CA 19-9 antigen are elevated in particular cancer
patients. Because each combination of capture antibody and
detection antibody makes a unique assay, the eight arrays for each
sample resulted in 288 (368) total capture-detection pairs and
candidate marker assays for each sample.
Before beginning the marker selection process, we culled the
data to remove the positive and negative control antibodies and
the assays that gave very weak signals over all the samples (see
methods section for criteria). A resulting set of 127 capture-
detection pairs was used in the subsequent analysis. The raw
fluorescence values were log transformed (base 10), which
converted the values from the 16-bit range of 0 to 65,535 to a
range of 1 to 4.82. The MSS program scanned through thresholds
over that range for each marker using a step of 0.2. This step size
was selected to balance the competing factors of processing time
and detail in the analysis. A comprehensive search of all
combinations of markers and all thresholds for each marker
uncovered a three-marker panel that had an accuracy (rate of
correct calls) of 89.9%, with a sensitivity of 89.3% and a specificity
of 90.8%. This performance is similar to that achieved by a variety
of other methods for developing multimarker classifiers (Table 1).
Cross validation is an important tool for estimating the
performance of a biomarker panel in future samples. A panel is
built from a subset of the available samples and then applied to the
remaining samples. That process can be repeated with several
different divisions of training sets and test sets. The average of the
performance of each biomarker panel on the test sets of samples
gives a reliable indicator of the robustness of a panel that can be
derived from the existing data. Cross validation was applied to the
sample set using the MSS method. Ten-fold cross validation was
used, meaning that the samples were divided into ten parts, and
for each iteration, a biomarker panel was built from nine parts and
applied to the tenth. The average accuracy of panels derived from
MSS was 84.7%, only slightly lower than the performance on the
entire data (Table 1). The fact that performance held up well in
the cross-validation test sets indicates good potential for continued
accuracy in future samples. This performance was similar to that
achieved by logistic regression (Table 1).
Next we sought to investigate more deeply the performance of a
single panel in a training set and a test set. Two thirds of all the
available sample data were used for a training set (to develop a
panel), and the remaining one third was set aside as a test set (to
Figure 1. Assigning patient classes and classifying marker
states. (A) Thresholding the data. Representative data for 21 samples
are presented, in which each point represents a patient sample
measurement for Marker 1 (left) or Marker 2 (right). A threshold (dashed
line) was applied to each marker. Values above the threshold are
converted to 1 and values below the threshold are converted to 0. (B)
Possible states. Each column represents a unique state for panels of 1, 2,
or 3 markers. (C) Determining marker states for each patient. The data
from both Marker 1 and Marker 2 are presented for each of the 21
patients, along with their respective thresholds (horizontal lines). The
thresholded data are below the column graph. Each sample has a
particular marker state (0,0; 0,1; 1,0; or 1,1). (D) State classification. Each
state is classified as either case or control based on whether cancer or
non-cancer samples have a greater number of occurrences in that state.
The ‘‘true positives’’ are the cancer samples that occupy case states, and
the ‘‘true negatives’’ are the non-cancer samples that occupy control
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test the panel). The two sets had equivalent percentages of cases
and controls. We used the results from cross validation analysis on
the training set to develop a candidate biomarker panel. We
reasoned that the most robust panel would have nearly the best
performance in each of the 10 iterations in cross validation and
that it would give good performance at many different thresholds
for each of the markers in the panel. The three-marker panel that
showed the best performance by these considerations was CA19-9
(Ab1)-CA19-9 (Ab1), Blood group A-Blood group B, and CA19-9
(Ab2)-CA19-9 (Ab1). (Each marker is defined by a capture
antibody and a detection antibody, indicated before and after the
dash.) We previously showed that the two CA 19-9 antibodies used
Figure 2. Determining optimal thresholds for a two-marker panel. (A) Scanning thresholds. Three different thresholds are depicted for
Marker 1 (left) and Marker 2 (right), with the resulting conversion to 1s and 0s for each threshold, followed by the sensitivities and specificities for
each marker at each threshold. (B) Determining the best combination of thresholds. All possible combinations of thresholds were assembled for the
two-marker panel, resulting in nine combinations. Based on the results from panel A, the numbers of cancer and non-cancer samples that occupy
each state were determined for each combination, from which the sensitivity and specificity could be calculated for each combination. The
combination of thresholds giving the best performance (in this case threshold 2 for Marker 1 and threshold 2 for Marker 2) is selected.
doi:10.1371/journal.pone.0065905.g002
Marker State Space
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here, Ab1 and Ab2, have differing and complementary specificities
[32], which provides a molecular understanding of their inclusion
together in a biomarker panel.
Before applying this panel to the test set, we used the entire
training set data to find the thresholds and state rules that gave the
best performance. The panel achieved 88.9% sensitivity, 86.0%
specificity, and 87.8% accuracy (Table 1). State 4 (0,1,1), state 6
(1,0,1), state 7 (1,1,0), and state 8 (1,1,1) were mainly occupied by
case samples and therefore were classified as case states (Fig. 3A).
State 1, state 3, and state 5 were classified as control states. State 2
(0,0,1) was not occupied by any sample but was classified as a
control state due to its similarity to the other control states. These
state rules can be condensed into a simplified rule that if a sample
is elevated in any two or more of the markers, it is called a ‘‘case’’
(Fig. 3A).
The application of this three-marker panel to the test set
achieved sensitivity of 85%, specificity of 96.2%, and accuracy of
89.4% (Fig. 4A). This performance held up well relative to the
training set (even slightly improved) and was similar to that
achieved by logistic regression (Table 1). The three-marker panel
selected by logistic regression shared two markers in common with
the MSS panel, and nearly all the samples were classified
equivalently by MSS and logistic regression (data not shown).
These analyses show that the MSS method can produce robust
multi-marker panels that have consistent performance in cross
validation and training set/test set analyses.
Subclasses defined by marker states
MSS enables a visualization of the marker states within the case
and control samples and the contributions of each marker to the
classifications, which may give insights into subclasses of patients
based on marker states. A view of the marker states of each sample
shows the relative proportions of the states (Figs. 3B and 4B).
Among the control samples, most of the true negatives were in
state 3 and state 1, with a small number in state 5, and the few false
positives were in state 8, state 7, and state 6. The true positive
samples were mainly in states 8 and 6, with a smaller number in
states 7 and 4, while the false negative samples were in states 3, 1,
and 5 (Figs. 3B and 4B). The relative occupancy of the states was
similar between the training and test sets (Fig. 5), which suggests
that these states would be consistent over a larger population.
We further tested the significance of these states by looking at
the relative proportion of different sample types within each state.
The control samples comprised both healthy subjects and patients
with pancreatitis. We found that the control samples occupying the
case states (the false positive samples) were predominantly from
pancreatitis patients (Fig. 5), which is consistent with pancreatitis
patients displaying more similarities to cancer patients than
healthy people. In a similar way, the false negative samples
primarily were from early-stage patients (stages I and II), rather
than late-stage patients, consistent with an expected greater
similarity of those patients to healthy people. Furthermore, we
observed that state 6 seemed to have a higher percentage of late-
stage cancer relative to state 8, as did state 1 relative to state 3.
State 6 (1,0,1) differs from state 8 (1,1,1) in that the Blood group A-
Blood group B marker is low, similar to the difference between
state 1 (0,0,0) and state 3 (0,1,0). The proportions were observed in
both the training and test sets, although their significance would
have to been determined in larger studies. The differences in
composition between states demonstrate the potential for using
MSS to identify molecular subclasses with distinct phenotypic
characteristics.
Discussion
New biomarkers are needed in a wide range of applications.
Because of the diversity between people and the possibility of
subclasses of disease, any single biomarker may not have the
performance needed to be clinically effective. The use of multiple
markers together in a panel is a good approach for dealing with
patient and disease diversity. Here we present a new method for
forming biomarker panels. Marker State Space is built on the
concepts that a set of all possible relationships (the state space)
exists among a given set of markers, and that certain states are
characteristic of disease. If we can accurately represent the
underlying biological relationships across cases, robust biomarker
performance should result. The method could be particularly
valuable when the markers that define one subgroup are different
from those that define another subgroup, or when the patterns of
expression among a common set of markers are different between
subgroups. MSS handles such diversity through the definition of
distinct and independent states among patients.
We demonstrated that MSS can identify markers panels with
robust performance in both cross validation and training set-test
set analyses. These analyses showed that the selected panels were
not ‘‘over fit,’’ or simply descriptive of only the training set data.
The performance was similar to other methods of developing
multi-marker classifiers. The fact that performance was similar
between all the methods tested (Table 1) likely reflects the facts
that the sample size is not large enough to reveal true differences in
performance and that a limited amount of information was
contained in these markers. The CA 19-9 marker, the current best
individual marker for pancreatic cancer [33], dominated the
classification, and the additional markers added a small amount of
accuracy to CA 19-9, similar to previous research [30]. It is likely
that no classification method will be best in every application; the
optimal classification method will depend on the relationships in
the data. The advantage of one method over another may appear
only in the analysis of very large datasets. Here we wanted to test
whether MSS could provide robust classification that was
comparable to other methods and whether MSS had other
practical advantages, as discussed below. The data show that MSS
can provide classification accuracy on par with other, established
methods, and that it may have advantages in certain settings.
The classification method bears resemblance to other methods
such as recursive partitioning and k-nearest neighbors, but with
some important distinctions. Recursive partitioning defines ‘‘case’’
states and ‘‘control’’ states based on discreet marker patterns, but
because of the sequential searching using only the best marker at
each division, the method may miss panels of markers that
individually do not provide discrimination information but rather
only in combination with specific other markers. K-nearest
neighbors shares with MSS the classification of samples based
on a vector of markers. The k parameter defines the size of the
subset of nearest neighbors to which an unknown sample is
matched, which presents a difficulty with unknown sizes of
subclasses. MSS makes no assumption about nearest neighbors (a
subclass of only one sample could be found). Another important
characteristic of MSS relative to other classification methods is its
suitability to clinical implementation, as it limits the number of
markers and uses simple classification rules that do not require
complex calculations. The use of small panels limits the cost of the
test and reduces technical complexity, so that any laboratory that
currently runs single assays could adopt a three-marker panel. The
thresholding of each marker measurement and classification of
each sample based on the pattern of three markers could be
immediately implemented without special computation.
Marker State Space
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The ability of MSS to identify patient subclasses based on
marker states was shown in two ways. First, the relative occupancy
of the marker states was consistent between the training and test
sets (Fig. 5), suggesting that these states are a natural feature of the
population of cancer patients, rather than a random observation.
Second, we observed differences in patient composition between
the states (Fig. 5), suggesting real biological or clinical differences
between the states. The high proportion of control patients with
benign pancreatic disease in the ‘‘case’’ states and the high
proportion of early-stage cancer patients in the ‘‘control’’ states
explained the origin of the false positive and false negative
identifications, respectively. These subsets of patients may be
fundamentally different from the correctly classified patients, and
additional markers may be necessary for their proper classification.
These types of analyses can be used to suggest molecular
classifications of patient subgroups and guide strategies for further
exploration of molecular characteristics.
The composition of the marker panels also gives information
about the states. The panel selected here used two different assays
for the CA 19-9 antigen. We previously showed that these two
Figure 3. Training set marker states and patient classifications. (A) Training set marker states. The eight possible marker states for the three
indicated markers are shown, followed by the numbers of case and control samples in each state and the categorization of each state. *State 2 was
unoccupied by categorized as a control state because of similarity to other control states. The lower panel shows condensed marker states, in which
X indicates either 0 or 1. (B) Individual sample classifications. Each column represents an individual patient sample, and the first three rows indicate
results from the indicated markers. A yellow square indicates the sample was above the threshold for that marker, and black indicates below. The
blue lines indicate the state in which each sample was classified.
doi:10.1371/journal.pone.0065905.g003
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antibodies have slightly different and complementary specificities
[32], similar to previous studies of antibodies directed against
glycan epitopes [34,35], so their use together in a single panel
could be expected to be beneficial. These two markers were
complemented by the detection of the blood group B epitope on
proteins captured by an antibody against blood group A (signified
Blood group A-Blood group B). Patients in state 4 or state 7 were
elevated in this marker and in only one of the CA 19-9 markers. A
relatively small number of patients were in state 4 or 7 (Fig. 5),
especially in the test set, but the appearance of these states suggest
that certain patients who do not fully elevate the CA 19-9 antigen
produce elevated levels of blood group A or blood group B
antigens. The ABO blood group antigens are carbohydrate
structures that are related to the carbohydrate structure defined
by the CA 19-9 antigen [36], so a biosynthetic shift from one to the
other in certain cancer patients would be possible. Additional
studies would be required to study the relationship between these
markers and the sources of variation between the patients.
The program and method could be further developed in various
ways. The software could be expanded to allow more detail in the
Figure 4. Test set marker states and patient classifications. The same marker panel, thresholds, and classification rules as shown in figure 4
were applied to the one-third of the total samples that were separated as a test set. (A) Occupancy of the marker states in the test set. (B) Individual
sample classifications in the test set.
doi:10.1371/journal.pone.0065905.g004
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analysis. For example, instead of using one threshold per marker to
convert each measurement to a 0 or 1, two thresholds could be
used, resulting in three levels (0, 1, or 2) for each measurement.
Such a modification might allow better modeling of situations in
which three biologically-driven levels of a marker might exist
across patients, such as abnormally low, moderate, and abnor-
mally high levels. In addition, the software could be modified to
select searches for panels including 3, 4, 5, or 6 markers, which
could allow for greater diversity in the markers that are selected
across patient states. The optimal panel size could be determined
using methods that have been worked out for other classification
algorithms, such as comparing change in performance from
training set to test set as panel size is increased. The continued use
of the method by additional researchers (the software is available
upon request) will provide more information about its perfor-
mance for biomarker research and reveal areas for further
development.
A limitation to implementing these approaches in the current
version of the software is the use of comprehensive searching to
find the best panel. Comprehensive searching allowed us to
identify the most robust panel for this data set, which represents an
advantage over approaches that trim data in a stepwise process, as
with recursive partitioning [16]. However, the run time for
comprehensive searches increases exponentially with the increase
in panel size or marker levels. The high search time might make
comprehensive searching impractical for large panels or for
datasets with many potential markers, as with gene expression
data. In this work we used small panels to reduce the chance of
overfitting, but to test the value of larger panels, alternate strategies
will be needed, such as developing an analytical understanding of
how to limit the search space or sampling the search space.
Sampling would cover the range of possible panels but not
comprehensively, thus running the risk of not finding the true
optimum. Limitations to the search space could be imposed to
allow comprehensive searching under constrained conditions. For
example, we could search only a subset of all possible states, such
as those with relatively simple classification rules. We demonstrat-
ed simplified classification rules in this work (Fig. 3A), reducing the
8 possible states for a 3-marker panel down to 6 states. In a similar
Figure 5. Composition of the states in the training and test
sets. The percentage of control samples (top panel) and case samples
(bottom panel) in each state is shown for both the training (dashed
columns) and test sets. Consistency between the training and test sets
in the relative occupancy between states is shown. The colors of the
bars indicate the composition of the subjects within each state. The
arrows indicate a high proportion of patients with benign disease
(pancreatitis) in the case states (top panel) and a high proportion of
early-stage cancer patients in the control state (bottom panel).
doi:10.1371/journal.pone.0065905.g005
Table 1. Comparison of performance between methods.
All Data (197 samples) 10-Fold Cross Validation*
Method Accuracy Sensitivity Specificity Accuracy Sensitivity Specificity
MSS 89.9% 89.3% 90.8% 84.7% – –
SVM 88.8% 88.4% 89.5% 87.3% 87.6% 86.8%
Logistic Regression 87.3% 89.3% 84.2% 87.3% 87.6% 86.8%
Naı¨ve Bayes 82.7% 77.7% 90.8% 82.7% 77.7% 90.8%
Neural Net 87.3% 88.4% 85.5% 85.3% 88.4% 80.3%
K-Nearest Neighbor 90.4% 90.9% 89.5% 85.3% 87.6% 81.6%
Training Set (131 samples) Test Set (66 samples)
Method Accuracy Sensitivity Specificity Accuracy Sensitivity Specificity
MSS 87.8% 88.9% 86.0% 89.4% 85.0% 96.2%
Logistic Regression 86.3% 87.7% 84.0% 92.4% 87.5% 100.0%
*The software did not calculate an average sensitivity and specificity for MSS in 10-fold cross validation because its does not separately calculate those parameters in
each cross validation split.
doi:10.1371/journal.pone.0065905.t001
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way, the 16 possible states for a 4-marker panel could be reduced
to a more manageable number of simplified states. It may be
possible to first find the simplified states by comprehensively
searching among smaller panels, and then to search for
combinations among more markers using just the simplified states.
These strategies will be explored as we further develop the use of
the method.
Another limitation of the current implementation of MSS in
comparison to some methods is that it cannot handle missing
values, because the classification of each sample requires a
complete, defined state. Approaches for dealing with missing data
[37] potentially could be developed for MSS, such as by
identifying partial states that are consistent with the observations
and predicting the likelihood of each complete state.
In summary, we anticipate that the MSS method will provide a
good complement to the existing approaches for developing
biomarker panels. The method may allow for an accurate
handling of subgroups within a population that have completely
divergent marker profiles, which may result in improved
performance over very large sample sizes. The simple computa-
tional process, involving the conversion of each measurement to
binary values followed by the classification of each sample based
on the marker state, should facilitate implementation in a wide
range of settings. Future applications of the method could
incorporate diverse data types, such as genotypes or clinical
features. Such data types may be particularly appropriate for the
MSS method because they indicate clear subgroups in popula-
tions.
Supporting Information
Figure S1 Antibody arrays with glycan detection. In this
example, three identical arrays containing three different antibod-
ies (AB1, AB2, and AB3) are incubated with plasma, and proteins
and captured according to the specificities of each antibody. Each
array is probed with a different detection antibody, AB4, AB5, or
AB6. The detection antibodies target specific glycan structures
attached to the proteins. The detection antibodies are tagged
(yellow circle) to allow measurements of their binding at each
capture antibody. Nine different combinations of capture
antibodies and detection antibodies are achieved
(PNG)
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